chronic antibody-mediated rejection
Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection
... These studies highlight the importance of TG as a marker of chronic damage and a poor prognosis. On the other hand, efficacy was based on graft function stabilization, which is difficult to distinguish from the ...
9
Expression of MMP-2 and TIMP-1 in Renal Tissue of Patients with Chronic Active Antibody-mediated Renal Graft Rejection
... humoral rejection and was included in Banff 07 pathologic diagnostic criteria, there- fore chronic active antibody-mediated rejection (AMR) was being paid more and more attention ...
6
Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis
... of rejection, a three-day-course of methylprednisolone 1000 milligram intravenous was initiated and a transplant biopsy was ...and chronic intermittent hemodialysis was ...
7
Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant Recipient
... plasmapheresis can be cumbersome, and it can be associated with several complications. The use of a short course of eculizumab (eg, only 2 doses of 600 mg each) could be considered cost-effective for the treatment of ...
7
Rituximab: An emerging therapeutic agent for kidney transplantation
... and antibody responses in solid-organ transplant ...of antibody-mediated rejection (AMR), post-transplant lymphoproliferative disorder (PTLD), and recurrent glomerular diseases in the renal ...
15
Bronchus associated lymphoid tissue–resident Foxp3+ T lymphocytes prevent antibody mediated lung rejection
... Antibody-mediated rejection (AMR) is a principal cause of acute and chronic failure of lung ...in rejection-free human lung grafts and accumulated within induced bronchus-associated ...
14
Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection
... of studies have indicated that the use of rituximab (RTX), tocilizumab, bortezomib, intravenous immunoglobulins (IVIG) therapy and/or plasmapheresis (PP), may favorably attenuate the loss of allograft function in ...
9
Bortezomib in late antibody mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
... ongoing antibody-mediated rejection (AMR) processes may critically contribute to late graft ...and chronic morphological lesions in 24-month protocol ...
9
CD4+ T-cell Mediated Microvascular Endothelial Cell Death and Chronic Cardiac Allograft Rejection Involves Necroptosis
... to antibody depletion of CD8 + cells or because of the fact that swine and humans constitutively express MHC Class II but mice and rats do ...in chronic rejection either directly by cytolytic effects ...
92
Antibody mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies
... Mechanisms and therapies. Endothelial cell injury and acti- vation lie at the heart of antibody-mediated allograft damage. Extensive in vitro evidence points to an intrinsic role for HLA sig- naling within ...
14
Clazakizumab in late antibody mediated rejection: study protocol of a randomized controlled pilot trial
... that antibody-medi- ated rejection (ABMR) is a leading cause of kidney allo- graft dysfunction and failure in the long-term ...and/or chronic morphological lesions in the microvascu- lature and, in ...
13
Eculizumab to Treat Antibody-Mediated Rejection in a 7-Year-Old Kidney Transplant Recipient
... plasmapheresis can be cumbersome, and it can be associated with several complications. The use of a short course of eculizumab (eg, only 2 doses of 600 mg each) could be considered cost-effective for the treatment of ...
7
Current perspectives on antibody-mediated rejection after lung transplantation
... of antibody-mediated rejection (AMR) in lung transplantation remain ...and chronic lung allograft dysfunction ...cellular rejection and CLAD. This has raised the possibility that ...
7
Prevention trumps treatment of antibody mediated transplant rejection
... to chronic and insidious alloantibody-mediated graft ...develop chronic rejection within 10 years — a daunting statistic, particularly for young patients expecting to achieve longevity by ...
5
Treatment of acute antibody-mediated rejection using Rituximab
... graft rejection causes by antibody were reported in transplanted patients who were undergoing by other treatments like ATG and PP and pulse corticosteroid and interestingly the four of them during 1 to 3 ...
7
Sirtinol regulates the balance of Th17/Treg to prevent allograft rejection
... In recent years, immunologists have paid more atten- tion to epigenetic regulation, which is thought to be the precise regulatory mechanism in immune cells. Trans- plant scientists focus on the mechanism by which epi- ...
10
Psychosocial challenges before and after organ transplantation
... Chronic illnesses are not only accompanied by somatic changes and functional limitations but also by emotional, cognitive, and social changes requiring extensive adjustments and considerable coping skills (Table ...
14
Defining housekeeping genes suitable for RNA-seq analysis of the human allograft kidney biopsy tissue
... It was reasoned that genes classified HKG in this study would have minimal representation in lists of genes known to be differentially expressed in disease states that affect the kidney. Accordingly, we sought overlaps ...
11
Delayed hyperacute rejection in a patient who developed <em>clostridium difficile</em> infection after ABO-incompatible kidney transplantation
... A1, A2, AB, and group B living donor kidneys. To date, 17 patients have undergone ABO blood type incompatible kidney transplantation with preimmunomodulation IgG titers as high as 1:1024. Our recipients have been ...
5
Immunosuppressive therapy with rituximab in common variable immunodeficiency
... severe antibody deficiency in adulthood and is character- ized by the reduction of serum immunoglobulin levels (namely IgG and IgA) and the impairment of antibody production in response to pathogens and ...
11